Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Announces Construction of New Manufacturing Facility for Active Pharmaceutical Ingredient of Prograf in Toyama Technology Center

share with twitter share with LinkedIn share with facebook
share via e-mail
01/17/2020 | 08:06am EDT

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced that the Third Fermentation Building (provisional name) will be constructed as a new manufacturing facility for active pharmaceutical ingredient (API) of Prograf (generic name: tacrolimus hydrate) in the Toyama Technology Center of Astellas Pharma Tech Co., Ltd., a production subsidiary of Astellas.

Prograf is an immunosuppressant discovered and developed by Astellas and currently marketed in approximately 100 countries / areas. It has greatly contributed to medical transplantation globally as a first-line immunosuppressant for organ transplantation. Sales of Prograf was JPY195.7 billion in FY2018.

Astellas is currently manufacturing API of Prograf for Japan and overseas as well as formulating and packaging in the Toyama Technology Center. The purpose of the construction of the Third Fermentation Building is to enhance our production capacity that will enable a stable supply of high-quality products in the future, taking into account the expected steady demand for Prograf and the status of the existing manufacturing facility in the Toyama Technology Center. It will also have state-of-the-art facilities based on the efficiency of the existing facilities.

The total construction cost will be approximately JPY10.0 billion, and the facility will have three above-ground floors and a total floor area of approximately 7,220 m2. The construction will be commenced in April 2020 and the completion is scheduled in August 2021.

This investment will have no impact on the financial results for the FY2019 ending March 31, 2020.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.


Tel: +81-3-3244-3201

Fax: +81-3-5201-7473

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
03/24CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop ..
03/23ASTELLAS PHARMA : CytomX Therapeutics and Astellas Announce Strategic Collaborat..
03/18ASTELLAS PHARMA : Gifu University and Astellas establish a Research Course on Ph..
02/27ASTELLAS PHARMA : Notice Regarding the Performance-linked Stock Compensation Sch..
02/20Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation fo..
02/19ASTELLAS PHARMA : and Seattle Genetics Receive FDA Breakthrough Therapy Designat..
02/12ASTELLAS PHARMA : XTANDI Demonstrates Significant Improvement in Overall Surviva..
02/11SEATTLE GENETICS : and Astellas Announce Updated Results from Phase 1b/2 Trial o..
02/06ASTELLAS PHARMA : Announces Management Structure
02/03ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancell..
More news
Financials (JPY)
Sales 2020 1 275 B
EBIT 2020 257 B
Net income 2020 204 B
Finance 2020 458 B
Yield 2020 2,37%
P/E ratio 2020 15,3x
P/E ratio 2021 15,3x
EV / Sales2020 2,15x
EV / Sales2021 2,06x
Capitalization 3 205 B
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 129,17  JPY
Last Close Price 1 724,50  JPY
Spread / Highest target 68,2%
Spread / Average Target 23,5%
Spread / Lowest Target -13,0%
EPS Revisions
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Senior Executive Officer & Head-Finance
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-13.23%324 693
ROCHE HOLDING AG-5.29%264 026
MERCK & CO., INC-21.13%181 927
NOVARTIS-16.30%180 007
PFIZER, INC.-21.13%171 422